Financial Statements and Highlights | Takeda Investor Relations

EN

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Sign up for our investors newsletter

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

Takeda to Hold Earnings Call for Fiscal Year 2025 3rd Quarter on January 29

January 15, 2026

Takeda Announces Global Collaboration and License Agreement with Halozyme to Continue Advancing Vedolizumab with ENHANZE® Drug-Delivery Technology

January 8, 2026

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 5, 2026

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

December 18, 2025

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline